Pharmaceutical

CPHI Europe: Overcoming the unique challenges with high...

High-concentration monoclonal antibodies (mAbs) are gaining prominence given the...

South Korean company Dong-A ST wins FDA approval for St...

Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for ...

FDA AdCom votes in favour of Stealth’s Barth syndrome drug

The Cardiovascular and Renal Drugs Advisory Committee voted 10-6 in support of S...

Global awareness and geographic variations of plaque ps...

Plaque psoriasis is a chronic condition that affects millions yet is often misun...

Roche wins first-line approval for PI3K inhibitor combo...

The US FDA approved Itovebi in combination with Pfizer’s Ibrance and AstraZeneca...

City Therapeutics launches with $135m Series A funding

City Therapeutics has announced its launch accompanied by a $135m Series A finan...

Ipsen’s Elafibranor gains MHRA approval for PBC treatment

Ipsen has received the UK MHRA's approval for its Elafibranor (Iqirvo) for the t...

Magazine: Cell and gene therapy approvals drive paradig...

In this issue: The manufacturing shift to meet growing cell and gene therapy dem...

Emergent to donate 20,000 Narcan doses to fight opioid ...

Emergent said it is separately working on increasing the availability of its ove...

Could preventative care save the future of the NHS?

As a major report highlights the challenges of a struggling NHS, the call for pr...

FDA declines to approve Zealand Pharma’s hypoglycaemia ...

The US FDA has declined to approve Zealand Pharma's dasiglucagon for hypoglycaem...

Purespring secures $105m to start Phase I/II trial of I...

Purespring Therapeutics has raised $105m in a Series B funding round which will ...

Clinical Dose Companies in Contract Manufacturing for t...

Discover the leading Clinical Dose Companies in Contract Manufacturing. Download...

Anima Biotech’s machine learning programme ‘reveals new...

The company employs machine learning to uncover disease mechanisms at the mRNA l...

MSD ventures into fibroblast therapies with $1.9bn deal...

The deal allows MSD to license one or more therapies against inflammatory diseas...

mRNA licensing agreements double with million-dollar deals

mRNA-based vaccines, which instruct cells to produce proteins that can prevent o...